{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:13:11Z","timestamp":1780546391716,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ceftolozane\/tazobactam (C-T) is a novel beta-lactam\/beta-lactamase inhibitor combination approved for the treatment of various infections caused by difficult-to-treat <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>. In critically ill patients, C-T may exhibit significant pharmacokinetic variability, both between individuals and within individuals, warranting therapeutic drug monitoring for clinical purposes. We aim to develop and validate a novel and sensitive analytical method for concurrently determining C and T in human plasma microsamples (3\u00a0\u03bcL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The method was developed using liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS) with positive electrospray ionization and multiple reaction monitoring (MRM) detection modes, employing specific mass transitions for both drugs. Sample preparation was simple, and the chromatographic run lasted only 4 minutes. Validation was conducted according to European Medicines Agency (EMA) guidelines, encompassing specificity, sensitivity, linearity, precision, accuracy, matrix effect, extraction recovery, limit of quantification, and drug stability. The validated method was applied to measure C and T in 32 plasma samples collected from critically ill patients with multidrug-resistant, gram-negative, bacterial infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The method ensured accurate (BIAS% 2.1\u20139.6 for C and \u22122.2 to 15.2 for T) and precise intraday CV% for C: 6.7\u20135.5; for T: 1.3\u20138.9; interday CV% for C 6.0\u201310.8; for T 4.1\u201310.2) measurements of C-T over a wide concentration range (0.2\u2013200.0 mg\/L for C and 0.1\u2013100.0 mg\/L for T). Overall, the recovery at quality control concentration levels was high for both C and T (mean values: 90\u201391 for C and 89\u201392 for T). Analyte stability was satisfactory in both human plasma and extracts under various storage conditions. The clinical applicability of the assay was confirmed by the reliably quantifying C and T in clinical plasma samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The developed and validated LC-MS\/MS method is sensitive and suitable for monitoring C and T in human plasma microsamples.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001236","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T18:25:37Z","timestamp":1722968737000},"page":"756-763","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Development and Validation of a Sensitive Liquid Chromatography\u2013Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Ceftolozane and Tazobactam in Human Plasma Microsamples"],"prefix":"10.1097","volume":"46","author":[{"given":"Matteo","family":"Conti","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; and"},{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy;"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Infect Drug Resist."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e01265","DOI":"10.1128\/AAC.01265-19","article-title":"Population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal dysfunction","volume":"63","author":"Sime","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/dkq449","article-title":"Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients","volume":"66","author":"Roberts","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkaa416","article-title":"Ceftolozane\/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK\/PD approach to tailor dosing","volume":"76","author":"Gatti","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4155\/bio-2017-0257","article-title":"Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma","volume":"10","author":"Ezquer","year":"2018","journal-title":"Bioanalysis"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/chromsci\/bmw047","article-title":"Development of an HPLC method for the determination of ceftolozane\/tazobactam in biological and aqueous matrixes","volume":"54","author":"Sutherland","year":"2016","journal-title":"J Chromatogr Sci."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpba.2018.09.044","article-title":"Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV","volume":"163","author":"Kratzer","year":"2019","journal-title":"J Pharm Biomed Anal."},{"key":"R9-20250603","first-page":"278","article-title":"A study on method development and validation of drugs used in hospital acquired bacterial pneumonia","volume":"12","author":"Krantikumar","year":"2022","journal-title":"J Eng Sci."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"114790","DOI":"10.1016\/j.biopha.2023.114790","article-title":"Analytical validation of a novel UHPLC-MS\/MS method for 19 antibiotics quantification in plasma: implementation in a LC-MS\/MS Kit","volume":"163","author":"Mula","year":"2023","journal-title":"Biomed Pharmacother."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"FSO352","DOI":"10.4155\/fsoa-2018-0079","article-title":"Development of an HPLC-MS\/MS method for the determination of ceftolozane\/tazobactam in bronchoalveolar lavage fluid","volume":"5","author":"Sutherland","year":"2019","journal-title":"Future Sci OA"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1515\/cclm-2020-1196","article-title":"A validated LC-MS\/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane\u2013tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies","volume":"59","author":"Parker","year":"2021","journal-title":"Clin Chem Lab Med."},{"key":"R13-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122354","article-title":"Development and validation of a quantitative LC-MS\/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine","author":"Putnam","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/antibiotics11010054","article-title":"Quantification of fosfomycin in combination with nine antibiotics in human plasma and cation-adjusted mueller-hinton II broth via LCMS","volume":"11","author":"Goh","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R15-20250603","first-page":"704","article-title":"Analytical method development and validation for the simultaneous estimation of ceftolozane and tazobactam in pure and pharmaceutical dosage form by RP-HPLC","volume":"10","author":"Subbareddy","year":"2019","journal-title":"Int J Res Pharm Sci."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"123496","DOI":"10.1016\/j.jchromb.2022.123496","article-title":"Automated HPLC-MS\/MS assay for the simultaneous determination of ten plasma antibiotic concentrations","volume":"15","author":"Magr\u00e9ault","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-20250603","article-title":"ICH M10 on bioanalytical method validation\u2014Scientific guideline","year":"2019","journal-title":"EMA"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.talanta.2017.05.049","article-title":"Some practical considerations for linearity assessment of calibration curves as function of concentration levels according to the fitness-for-purpose approach","volume":"172","author":"Jurado","year":"2017","journal-title":"Talanta"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/antibiotics12020213","article-title":"Fast and sensitive analysis of cefiderocol in human plasma microsamples by liquid chromatography-isotope dilution tandem mass spectrometry for therapeutic drug monitoring","volume":"12","author":"Barone","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/pharmaceutics15020480","article-title":"Fast and simple liquid chromatography-isotope dilution tandem mass spectrometry method for therapeutic drug monitoring of dalbavancin in long-term treatment of subacute and\/or chronic infections","volume":"15","author":"Barone","year":"2023","journal-title":"Pharmaceutics"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/antibiotics12040719","article-title":"Fast and sensitive method for simultaneous quantification of meropenem and vaborbactam in human plasma microsamples by liquid chromatography-tandem mass spectrometry for ther drug monit","volume":"12","author":"Barone","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FTD.0000000000001158","article-title":"Fast and sensitive analysis of fosfomycin in human plasma microsamples using liquid chromatography\u2013tandem mass spectrometry for therapeutic drug monitoring","volume":"46","author":"Barone","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"114900","DOI":"10.1016\/j.jpba.2022.114900","article-title":"Evaluation of 4 quantification methods for monitoring 16 antibiotics and 1 beta-lactamase inhibitor in human serum by high-performance liquid chromatography with tandem mass spectrometry detection","volume":"219","author":"Seraissol","year":"2022","journal-title":"J Pharm Biomed Anal."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s43440-023-00509-w","article-title":"Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application","volume":"75","author":"Kocur","year":"2023","journal-title":"Pharmacol Rep."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jpba.2017.07.033","article-title":"Volumetric adsorptive microsampling-liquid chromatography tandem mass spectrometry assay for the simultaneous quantification of four antibiotics in human blood: method development, validation and comparison with dried blood spot","volume":"145","author":"Barco","year":"2017","journal-title":"J Pharm Biomed Anal."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/FTD.0000000000001105","article-title":"Developing a method for quantifying meropenem in children\u2014volumetric adsorptive microsampling versus plasma sampling","volume":"45","author":"Ramadan","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fped.2022.1055200","article-title":"Applicability of vancomycin, meropenem, and linezolid in capillary microsamples vs. dried blood spots: a pilot study for microsampling in critically ill children","volume":"10","author":"Xiaoyong","year":"2023","journal-title":"Front Pediatr."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:46Z","timestamp":1748970886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001236","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"2024-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}